Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma reported consolidated revenue of ₹1,390.6 crore for Q1FY26, down slightly from ₹1,410.7 crore in Q1FY25. Consolidated net profit fell sharply to ₹480.3 crore (from ₹668.5 crore YoY), impacted by pricing pressure in the US product portfolio and higher R&D spending on high-value projects. EBITDA stood at ₹632.7 crore with margins of 45.5%. The Board declared an interim dividend of ₹2 per share (100%) with a record date of August 19, 2025, and approved increasing authorised capital to ₹45 crore (22.5 crore equity shares of ₹2 each), subject to shareholder approval. Auditor BSR and Co issued an unmodified limited review report on both standalone and consolidated results.
Despite a sharp YoY drop in profits, the company maintained strong EBITDA margins of 45.5% and rewarded shareholders with a 100% interim dividend. The capital increase signals potential fund-raising plans, while US pricing pressure and elevated R&D costs are near-term concerns for margins and growth.